Physician profile
Douglas K Grayson
NPI 1689674129
$158,253.23
in general payments reported to CMS, 2019-2025
23 companies · $45K in 2025
The $45K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,970 · 2020: $9,282 · 2021: $8,901 · 2022: $14K · 2023: $22K · 2024: $57K · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $58K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37K · Food and Beverage: $20K · Honoraria: $7,900 · Travel and Lodging: $390 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $58,332.42 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,462.50 |
| Food and Beverage | $19,500.89 |
| Honoraria | $7,900.00 |
| Travel and Lodging | $390.41 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $45,286.51 | 2019-2025 | Clareon, Acrysof Iq Panoptix Uv Iol, Acrysof Iq Vivity |
| Johnson & Johnson Surgical Vision, INC. | $40,979.21 | 2019-2025 | Tecnis Iol, Tecnis Iol, Tecnis Simplicity |
| Glaukos Corporation | $23,669.26 | 2019-2025 | Istent Trabecular Micro-Bypass Stent System, Idose, Idosetr |
| New World Medical,INC. | $22,800.96 | 2019-2025 | Streamline, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Abbvie INC. | $15,281.83 | 2022-2025 | |
| Allergan, INC. | $3,288.32 | 2019-2021 | |
| Alcon Research LLC | $1,750.00 | 2020 | |
| Sight Sciences, INC. | $1,626.96 | 2020-2025 | Omni Surgical System, Sion Surgical Instrument |
| Rxsight INC | $787.69 | 2024-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Bausch & Lomb Americas INC. | $784.12 | 2022-2025 | Miebo, Vyzulta |
| Harrow Eye, LLC | $429.11 | 2024-2025 | Vevye |
| Topcon Healthcare, INC. | $347.11 | 2023-2025 | |
| Biotissue Holdings INC. | $250.34 | 2021-2023 | |
| Carl Zeiss Meditec Cataract Technology INC. | $192.37 | 2023 | |
| Genzyme Corporation | $191.30 | 2022-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $138.98 | 2023-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $120.72 | 2019 | |
| Omeros Corporation | $118.37 | 2019 | |
| Ivantis, INC | $92.43 | 2021 | |
| Carl Zeiss Meditec, INC. | $51.44 | 2019 | |
| Ocular Therapeutix, INC. | $29.70 | 2021-2023 | Dextenza |
| Tarsus Pharmaceuticals, INC. | $22.38 | 2024 | Xdemvy |
| Boston Scientific Corporation | $14.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Grayson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.